REMARKS

The Examiner rejected claims 71 and 76 to 86 on the ground of non-statutory obviousness-type double patenting as being unpatentable over claim 15 and claims 2 to 6 of U.S. Patents Nos. 6,287,604 and 6,312,732 respectively. A rejection of obviousness-type double patenting may be overcome by the submission of a Terminal Disclaimer.

Submitted herewith are two Terminal Disclaimers disclaiming the terms of the patent to be granted on this application which may extend beyond the term of each of U.S. Patent Nos. 6,287,604 and 6,312,732, signed by an attorney of record. Authorization to charge the prescribed fee to our deposit account is enclosed.

Having regard thereto, it is submitted that claims 71 and 76 to 86 are no longer object to rejection on the ground of non-statutory obviousness-type double patenting and hence the rejection should be withdrawn.

The Examiner rejected claims 71 to 86 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The Examiner raised a number of matters:

- The Examiner refers to claim 1. It is presumed that the Examiner intended to refer to claim 71. Claim 71 has been amended to clarify that there are two carriers, the particulate carrier for the immunogen particulate which is chemically bound to the particulate carrier, with appropriate amendment of the definition of R_6. There is a physiologically acceptable carrier for the particulate carrier (and the attached immunogen). Claim 71 has been further amended to relocate the formula in the claim. It has been clarified that "said carrier" is "said particulate carrier".

RECEIVED
CENTRAL FAX CENTER
DEC 0 4 2006

- In claims 77 and 83, the term "derived" has been changed to "formed".

- In claim 79, the misspelling of "hydroxyl" has been corrected.

- Claim 86 has been deleted as redundant having regard to the amendment to claim 71.

It is submitted that claims 71 to 86 can no longer be considered to be indefinite and hence the rejection thereof under 35 U.S.C., second paragraph, should be withdrawn.

It is believed that this application is now in condition for allowance and early and favourable consideration and allowance are respectfully requested.

Respectfully submitted,

Michael I. Stewart
Reg. No. 24,973

Toronto, Ontario, Canada,
Phone No.: (416) 849-8400
FAX No.: (416) 595-1163